OBJECTIVES: To characterize comorbidities, health-related quality-of-life (HRQoL), productivity, and healthcare resource use among adults with atopic dermatitis (AD) relative to those without AD, and to evaluate the impact of patient-reported AD severity on these outcomes. METHODS: Data were from the 2013 NHWS, which collected self-reported information on demographics, comorbidities, HRQoL (SF-36 Health Survey), productivity (Work Productivity and Impairment questionnaire [WPAI]), and healthcare utilization, which were weighted to the US general population. The AD cohort consisted of subjects who reported they experienced AD within the past 12 months (n=428), and the non-AD cohort was all other subjects who did not experience AD within the past 12 months (n=74,572); 366 AD subjects reported disease severity as mild (n=182), moderate (n=148), or severe (n=36). Univariable and multivariable analyses compared characteristics and outcomes between cohorts and across severity levels. RESULTS: The AD cohort was younger than non-AD subjects (44.3 vs 46.6 years; P=0.0033), and had a higher proportion of females (64.4% vs 51.8%; P<0.0001). Relative to the non-AD cohort, AD subjects had a significantly greater prevalence of atopic conditions including nasal allergies (46.4% vs 19.8%) asthma (22.4% vs 7.9%), neuropsychiatric conditions such as anxiety (42.5% vs 21.3%), depression (37.2% vs 20.9%), and attention deficit hyperactivity disorder (4.5% vs 1.1%) (all P<0.0001). Units of resource use (healthcare practitioner visits, emergency room, hospitalizations) were greater (all P<0.05) and HRQoL was poorer (P<0.0001) with AD. On the WPAI, employed AD subjects reported almost twice as much lost work productivity as non-AD employees (30.0% vs 16.3%; P<0.0001). No clear patterns were observed across patient-reported AD severity categories on any outcome. CONCLUSIONS: The significant burden associated with AD relative to those without AD suggests an unmet need for more effective management strategies. There also appears a need for greater characterization of disease severity from the patient perspective.